Enterprise Value

559.6M

Cash

482.9M

Avg Qtr Burn

-21.04M

Short % of Float

16.83%

Insider Ownership

0.78%

Institutional Own.

80.58%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DEXTENZA® (dexamethasone ophthalmic insert) Details
Inflammation and pain following ophthalmic surgery

Approved

Quarterly sales

ReSure® Sealant Details
Intraoperative management of clear corneal incision

Approved

Quarterly sales

DEXTENZA® (dexamethasone ophthalmic insert) Details
Eye disease , Allergic conjunctivitis

Approved

Quarterly sales

Phase 3

Data readout

Phase 2

Data readout

Phase 2

Data readout

PAXTRAVA™ (OTX-TIC) (travoprost implant) Details
Ocular hypertension, Primary open angle glaucoma

Phase 2

Update

Phase 1

Update